secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001104659-23-074513
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports non-clinical data showing MT-401 + HMA synergy; awarded $2M NIH grant
--------------------------------------------------------------------------------

- Non-clinical in vitro data: MT-401 after HMA (5'-Azacytidine) significantly decreased AML THP-1 cell growth vs. either agent alone, suggesting synergy.
- NIH SBIR grant of $2 million will fund a nationwide multi-center Phase 2b trial of MT-401 with HMA pre-treatment in AML patients post-HSCT.
- MT-401 targets four antigens (Survivin, PRAME, WT-1, NY-ESO-1); HMA upregulated Survivin expression in AML cells.
- Company plans to incorporate findings into current AML clinical study; revised design details expected in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923074513/0001104659-23-074513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923074513/tm2319618d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-074513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer